HOME >> MEDICINE >> NEWS
Clinical Trials Units selected for newly restructured HIV/AIDS research networks

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced 60 U.S. and international institutions selected as HIV/AIDS Clinical Trials Units (CTUs) in a newly restructured system of six HIV/AIDS clinical research networks. NIAID expects to fund additional CTUs within the next several months, bringing the total to 73.

These Clinical Trials Units will carry out the next generation of HIV/AIDS vaccine, prevention and treatment research, says NIAID Director Anthony S. Fauci, M.D. They will work with our clinical research networks in a flexible, collaborative and coordinated way to tackle the critical research questions that can help accelerate progress against the HIV/AIDS pandemic. NIAID supports the worlds largest HIV/AIDS clinical research effort.

The CTU awards represent the second step of a two-part restructuring process of NIAIDs HIV/AIDS clinical trials networks. NIAID announced the clinical investigators and institutions responsible for leading the new networks in June 2006 (see http://www3.niaid.nih.gov/news/newsreleases/2006/leadership.htm).

Each CTU is a member of one or more of the six NIAID HIV/AIDS networks: the AIDS Clinical Trials Group, the HIV Prevention Trials Network, the HIV Vaccine Trials Network, the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, the International Network for Strategic Initiatives in Global HIV Trials, and the Microbicide Trials Network.

The HIV/AIDS networks and their CTUs will pursue an integrated research approach to conducting clinical trials designed to address the highest priorities in HIV/AIDS research, including

  • Developing a safe and effective HIV vaccine

  • Conducting research for new drug development designed to translate lab findings into clinical applications


'"/>

Contact: Kathy Stover
kstover@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
12-Mar-2007


Page: 1 2 3

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
8. Clinical trial coordinators need more financial conflict-of-interest training
9. Clinical studies evaluate potential treatments for mouth ulcers
10. NIH names Clinical Trial Units for the Microbicide Trials Network
11. Study in recent issue of Clinical Pediatrics helps pediatricians to understand discipline practices

Post Your Comments:
(Date:7/25/2014)... (PRWEB) July 25, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Ibuprofen and Oxcarbazepine ... that one lot of Ibuprofen and one lot of Oxcarbazepine ... due to mislabeled packaging. Oxcarbazepine is used for the treatment ... , The reason for the recall is that Lot ...
(Date:7/25/2014)... July 25, 2014 Parker Waichman LLP, ... of consumers comments on a recent tobacco lawsuit in ... smoker $23.6 billion in punitive damages. Cynthia Robinson brought ... cigarettes. The case is Cynthia Robinson v. R.J. Reynolds ... Florida First Circuit Court, Escambia County, Florida; Case Number ...
(Date:7/25/2014)... Drexel University College of Medicine is pleased ... been appointed vice dean for education, effective October 1, 2014. ... Medical College, where she is currently chair of the Department ... of medicine. , As a member of the senior ... major role in many aspects of the development of the ...
(Date:7/25/2014)... vulnerable neurons and reduce motor deficits in a ... University School of Medicine have shown. , The ... Parkinson,s Disease . , The findings demonstrate that ... at sufficient levels and have beneficial effects when ... Previous studies of XPro1595 in animals tested more ...
(Date:7/25/2014)... 25, 2014 The new report ... Feed, Pharmaceuticals and Others), by Type (Amylases, Cellulases, ... Geography - Global Trends & Forecasts to 2019", ... of the global Carbohydrase market with analysis of ... is segmented and values are forecasted on the ...
Breaking Medicine News(10 mins):Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... July 24, 2014 Amgen (NASDAQ: AMGN ... financial results on Tuesday, July 29, 2014, after the close ... by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, ... Live audio of the conference call will be simultaneously broadcast ...
(Date:7/24/2014)... British Columbia and MENLO PARK, Calif. ... Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today that ... company,s fiscal year from December 31 to June 30. Accordingly, ... September 30, 2014. Jeffrey Bacha , president ... end is an important step in achieving our goal of ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
Cached News: